Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

INSANE: Nektar therapeutics s return on capital employed insights | Rare Historical Photos

According to Benzinga Pro data, during Q1, Nektar Therapeutics (NASDAQ:NKTR) posted sales of $24.82 million. Earnings were up 37.94%, but Nektar Therapeutics still reported an overall loss of $90.39 million. Nektar Therapeutics collected $25.01 million in revenue during Q4, but reported earnings showed a $145.65 million loss.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.